Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 3 (2006), Issue 2 (February)

1. Growth inhibition and apoptosis induced by daunomycin-conjugated triplex-forming oligonucleotides targeting the c-myc gene in prostate cancer cells.
   Nucleic Acids Res, 34(2): 734-44. [Abstract] [Full-text]
2. Regulation of prostate cell collagen receptors by malignant transformation.
   Int J Cancer, 118(4): 889-98. [Abstract] [Full-text]
3. Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition.
   Int J Cancer, 118(4): 1041-50. [Abstract] [Full-text]
4. Expression of dentin sialophosphoprotein in human prostate cancer and its correlation with tumor aggressiveness.
   Int J Cancer, 118(4): 850-6. [Abstract] [Full-text]
5. Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells.
   Int J Cancer, 118(4): 1022-31. [Abstract] [Full-text]
6. Differential expression of TGFbeta-stimulated clone 22 in normal prostate and prostate cancer.
   Int J Cancer, 118(4): 899-906. [Abstract] [Full-text]
7. Vitamin antioxidants, lipid peroxidation and the systemic inflammatory response in patients with prostate cancer.
   Int J Cancer, 118(4): 1051-3. [Abstract] [Full-text]
8. Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment.
   BMC Cancer, 6: 15. [Abstract] [Full-text]
9. Influence of number of CAG repeats on local control in the RTOG 86-10 protocol.
   Am J Clin Oncol, 29(1): 14-20. [Abstract] [Full-text]
10. Tolerance of endorectal balloon in 396 patients treated with intensity-modulated radiation therapy (IMRT) for prostate cancer.
    Am J Clin Oncol, 29(1): 8-11. [Abstract] [Full-text]
11. Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway.
    Cell, 124(3): 615-29. [Abstract] [Full-text]
12. Combination of methylated-DNA precipitation and methylation-sensitive restriction enzymes (COMPARE-MS) for the rapid, sensitive and quantitative detection of DNA methylation.
    Nucleic Acids Res, 34(3): e19. [Abstract] [Full-text]
13. Sensitization to gimatecan-induced apoptosis by tumor necrosis factor-related apoptosis inducing ligand in prostate carcinoma cells.
    Biochem Pharmacol, 71(6): 791-8. [Abstract] [Full-text]
14. Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells.
    Biochem Pharmacol, 71(6): 751-60. [Abstract] [Full-text]
15. TRB3 is a PI 3-kinase dependent indicator for nutrient starvation.
    Cell Signal, 18(6): 899-909. [Abstract] [Full-text]
16. Gene promoter methylation in prostate tumor-associated stromal cells.
    J Natl Cancer Inst, 98(4): 255-61. [Abstract] [Full-text]
17. Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk.
    J Natl Cancer Inst, 98(4): 245-54. [Abstract] [Full-text]
18. EGFR signaling pathway negatively regulates PSA expression and secretion via the PI3K-Akt pathway in LNCaP prostate cancer cells.
    Biochem Biophys Res Commun, 342(1): 92-100. [Abstract] [Full-text]
19. Inactivation of Id-1 in prostate cancer cells: A potential therapeutic target in inducing chemosensitization to taxol through activation of JNK pathway.
    Int J Cancer, 118(8): 2072-81. [Abstract] [Full-text]
20. Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour xenografts in SCID mice.
    Br J Cancer, 94(4): 513-23. [Abstract] [Full-text]
21. The feasibility and results of a population-based approach to evaluating prostate-specific antigen screening for prostate cancer in men with a raised familial risk.
    Br J Cancer, 94(4): 499-506. [Abstract] [Full-text]
22. Feasibility of familial PSA screening: psychosocial issues and screening adherence.
    Br J Cancer, 94(4): 507-12. [Abstract] [Full-text]
23. E-cadherin polymorphisms and haplotypes influence risk for prostate cancer.
    Prostate, 66(5): 546-56. [Abstract] [Full-text]
24. PAC1-R null isoform expression in human prostate cancer tissue.
    Prostate, 66(5): 514-21. [Abstract] [Full-text]
25. Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma.
    Prostate, 66(5): 503-13. [Abstract] [Full-text]
26. Enhancement of intermittent androgen ablation by "off-cycle" maintenance with finasteride in LNCaP prostate cancer xenograft model.
    Prostate, 66(5): 495-502. [Abstract] [Full-text]
27. Prostatic fluid concentrations of isoflavonoids in soy consumers are sufficient to inhibit growth of benign and malignant prostatic epithelial cells in vitro.
    Prostate, 66(5): 557-66. [Abstract] [Full-text]
28. Murine androgen-independent neuroendocrine carcinoma promotes metastasis of human prostate cancer cell line LNCaP.
    Prostate, 66(5): 536-45. [Abstract] [Full-text]
29. Gene therapy for prostate cancer: current strategies and new cell-based approaches.
    Prostate, 66(5): 470-94. [Abstract] [Full-text]
30. Synthetic dimer of indole-3-carbinol: second generation diet derived anti-cancer agent in hormone sensitive prostate cancer.
    Prostate, 66(5): 453-62. [Abstract] [Full-text]
31. Expression of prothymosin alpha is correlated with development and progression in human prostate cancers.
    Prostate, 66(5): 463-9. [Abstract] [Full-text]
32. Serum hepatocyte growth factor activator inhibitor type I (HAI-I) and type 2 (HAI-2) in prostate cancer.
    Prostate, 66(5): 447-52. [Abstract] [Full-text]
33. Prognostic significance of osteopontin expression in human prostate cancer.
    Int J Cancer, 118(9): 2255-61. [Abstract] [Full-text]
34. A prostate secretory protein94-derived synthetic peptide PCK3145 inhibits VEGF signalling in endothelial cells: implication in tumor angiogenesis.
    Int J Cancer, 118(9): 2350-8. [Abstract] [Full-text]
35. Steroid hormones stimulate human prostate cancer progression and metastasis.
    Int J Cancer, 118(9): 2123-31. [Abstract] [Full-text]
36. Management of prostate cancer. Part 1: chemoprevention.
    Expert Rev Anticancer Ther, 6(3): 419-25. [Abstract] [Full-text]
37. Cluster model analysis of late rectal bleeding after IMRT of prostate cancer: a case-control study.
    Int J Radiat Oncol Biol Phys, 64(4): 1255-64. [Abstract] [Full-text]
38. Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10.
    Int J Radiat Oncol Biol Phys, 64(4): 1162-7. [Abstract] [Full-text]
39. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer.
    Int J Radiat Oncol Biol Phys, 64(4): 1151-61. [Abstract] [Full-text]
40. Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix.
    Life Sci, 78(16): 1784-93. [Abstract] [Full-text]
41. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
    Int J Radiat Oncol Biol Phys, 64(4): 1140-50. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.